The National Institute for Heath and Clinical Excellence has withdrawn its guidance on the use of rimonabant for the treatment of overweight and obese patients.
The withdrawal of this guidance is as a result of suspension of the marketing authorisation for rimonabant (Acomplia®) by the European Medicines Agency (EMEA) for safety reasons.
Action: Clinicians should already be aware of this license suspension. No new prescriptions should be issued and patients should be advised that it is safe to stop treatment at any time.
|« Cardiovascular outcomes and diabetes medications||Fracture prevention quick reference guides »|